DeepCure

AI-driven Drug Discovery

Health Tech & Life Sciences
Active
Series A Boston, United States Founded 2018
Total raised
$46.0M
Last: Series A 2021-11
Stage
Series A
Founded
2018
Headcount
32
HQ
Boston, United States
Sector
Health Tech & Life Sciences

About

DeepCure developed an AI platform designed to search the enormous chemical space with high accuracy. By combining the power of its deep learning algorithms, cloud computing infrastructure, and proprietary database of 1 trillion chemistries, DeepCure's platform finds drug candidates that deliver improved value to patients.

DeepCure's proprietary molecular database, MolDB, is a large medicinal chemistry database that covers over 1 trillion compounds and is expanded on demand to 1 quintillion molecules. These compounds are highly diverse and span most of the chemical space currently accessible to chemists. The trillion compounds cover more than 75% of existing medicinal chemistry compounds, including drugs and current clinical candidates in development, synthesized, or reported by medicinal chemists.

In addition, a suite of generative models can expand each selected molecule to a million analogs, expanding the search even further to 1 quintillion (10^18) molecules.

MolDB enables the discovery of candidates that don't exist in traditional screening libraries.

Funding history · 2 rounds · $46.0M total

2021-11
Series A $40.0M
2019-08
Seed $6.0M

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Artificial IntelligenceDeep Learning
Target customers
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticals
Business model
B2B

Tags

drug-developmentdrug-discoverybiotechnologypharmaceuticalsartificial-intelligencedeep-learning